Healthcare · Biotechnology
Price
$15.79
Market Cap
$986.2M
Employees
56
Beta
1.74
Avg Volume
366,080
CEO
Pratik Shah
Business Description
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
Business History
Price Overview
Last updated: May 14, 2026 3:16am (just now)$15.62
-0.17 (-1.08%)
Day Range
$15.23 – $15.95
52-Week Range
$3.11 – $17.25
50-Day MA
$12.10
200-Day MA
$8.81
Volume
752,413.00
Analyst Price Targets
Low
$14.00
Consensus
$17.50
High
$21.00
(10 analysts)
Share Structure
Outstanding
62,456,974.00
Float
36,734,084.00
Free Float
58.8%
Normal free float
— 58.8% of shares trade freely, ~41.2% held by insiders/institutions
Healthy float typical of established companies. Good liquidity for entering and exiting positions without major price impact.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-12.94
Stock Price: $15.79
EPS (Diluted): -1.22
EPS (Diluted): -1.22
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
2.53
Stock Price: $15.79
Total Equity: $212.50M
Shares: 57,330,192
Total Equity: $212.50M
Shares: 57,330,192
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-13.17
Market Cap: $986.20M
Total Debt: $645,000
Cash: $16.86M
EBITDA: -$78.85M
Total Debt: $645,000
Cash: $16.86M
EBITDA: -$78.85M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$521.5M
Market Cap: $986.20M
Total Debt: $645,000
Cash: $16.86M
Total Debt: $645,000
Cash: $16.86M
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: -$622,000
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$79.47M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$69.79M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-33.1%
Net Income: -$69.79M
Total Equity: $212.50M
Total Equity: $212.50M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-35.7%
Operating Income: -$79.47M
Tax Rate: 0.0%
Equity: $212.50M
Total Debt: $645,000
Cash: $16.86M
Tax Rate: 0.0%
Equity: $212.50M
Total Debt: $645,000
Cash: $16.86M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
17.14
Current Assets: $223.78M
Current Liabilities: $13.06M
Current Liabilities: $13.06M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $645,000
Total Debt: $645,000
Total Equity: $212.50M
Long-Term Debt: $645,000
Total Debt: $645,000
Total Equity: $212.50M
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 57,330,192
Shares: 57,330,192
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$3.71
Total Equity: $212.50M
Shares: 57,330,192
Shares: 57,330,192
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-0.95
Operating CF: -$54.36M
CapEx: -$193,000
Shares: 57,330,192
CapEx: -$193,000
Shares: 57,330,192
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $15.79
Stock Price: $15.79
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$69.79M
Net Income: -$69.79M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares DSGN against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: May 9, 2026 7:27pm (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $466,000 | $537,000 | $596,000 | $622,000 |
| Gross Profit | $0 | $-466,000 | $-537,000 | $-596,000 | $-622,000 |
| Operating Expenses | $35.8M | $67.1M | $77.7M | $61.8M | $78.8M |
| Operating Income | -$35.8M | -$67.6M | -$78.2M | -$62.4M | -$79.5M |
| Net Income | -$35.5M | -$63.3M | -$66.9M | -$49.6M | -$69.8M |
| EBITDA | -$35.7M | -$62.8M | -$66.3M | -$49.0M | -$78.8M |
| EPS | $-0.77 | $-1.14 | $-1.19 | $-0.88 | $-1.22 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: May 9, 2026 7:27pm (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $298.6M | $26.5M | $21.2M | $22.6M | $16.9M |
| Total Current Assets | $385.4M | $335.1M | $284.6M | $248.0M | $223.8M |
| Total Assets | $390.6M | $341.1M | $289.6M | $252.1M | $226.2M |
| Current Liabilities | $5.3M | $10.8M | $9.6M | $8.5M | $13.1M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $645,000 |
| Total Liabilities | $8.4M | $13.8M | $12.0M | $10.0M | $13.7M |
| Total Equity | $382.1M | $327.3M | $277.7M | $242.1M | $212.5M |
| Retained Earnings | -$47.5M | -$110.8M | -$177.6M | -$227.2M | -$297.0M |
Cash Flow (Annual)
Last updated: May 9, 2026 7:27pm (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$29.4M | -$51.3M | -$58.6M | -$43.1M | -$54.4M |
| Capital Expenditure | -$1.5M | $-918,000 | $-256,000 | $-340,000 | $-193,000 |
| Free Cash Flow | -$30.9M | -$52.2M | -$58.8M | -$43.4M | -$54.6M |
| Acquisitions (net) | $52,106 | $39,000 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $296.2M | -$272.1M | -$5.3M | $1.4M | -$5.7M |
Analyst Estimates (Annual)
Last updated: May 13, 2026 7:35am (19h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$204.8M $204.8M – $204.8M
|
$8.5M $8.5M – $8.5M
|
$72.7M $72.7M – $72.7M
|
$234.1M $234.1M – $234.1M
|
| EBITDA | $0 | $0 | $0 | $0 |
| Net Income |
-$97.9M -$116.5M – -$79.4M
|
-$114.0M -$140.6M – -$87.3M
|
-$97.9M -$97.9M – -$97.9M
|
-$27.4M -$27.4M – -$27.4M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: May 9, 2026 7:27pm (4d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | — |
| Gross Profit Growth | — | -15.2% | -11.0% | -4.4% |
| Operating Income Growth | -88.6% | -15.7% | +20.2% | -27.4% |
| Net Income Growth | -78.2% | -5.6% | +25.8% | -40.7% |
| EBITDA Growth | -76.0% | -5.5% | +26.1% | -60.9% |
Insider Trading (Recent)
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-03-31 | Shapiro David | A-Award | 60,000.00 | $10.64 | $638,400 |
| 2026-03-31 | Shapiro David | A-Award | 7,500.00 | $10.64 | $79,800 |
| 2026-03-31 | Shapiro David | 0.00 | $0.00 | $0 | |
| 2026-01-02 | Storgard Chris | A-Award | 250,000.00 | $9.10 | $2.3M |
| 2026-01-02 | Jeffries Sean | A-Award | 375,000.00 | $9.10 | $3.4M |
| 2026-01-02 | Burgess Julie | A-Award | 150,000.00 | $9.10 | $1.4M |
| 2026-01-02 | Gover Justin D. | A-Award | 45,000.00 | $9.10 | $409,500 |
| 2026-01-02 | Shah Pratik | A-Award | 750,000.00 | $9.10 | $6.8M |
| 2025-12-09 | Shah Pratik | A-Award | 525,000.00 | $2.48 | $1.3M |
| 2025-09-09 | Gover Justin D. | A-Award | 30,000.00 | $6.64 | $199,200 |
| 2025-09-09 | Gover Justin D. | A-Award | 15,833.00 | $6.64 | $105,131 |
| 2025-09-09 | Gover Justin D. | 0.00 | $0.00 | $0 | |
| 2025-08-13 | William Arsani | S-Sale | 345,000.00 | $5.25 | $1.8M |
| 2025-08-13 | William Arsani | S-Sale | 217,627.00 | $5.25 | $1.1M |
| 2025-06-10 | George Simeon | A-Award | 19,000.00 | $4.01 | $76,190 |
| 2025-06-10 | Prasad Deepa | A-Award | 19,000.00 | $4.01 | $76,190 |
| 2025-06-10 | William Arsani | A-Award | 19,000.00 | $4.01 | $76,190 |
| 2025-06-10 | Berger Heather A. | A-Award | 19,000.00 | $4.01 | $76,190 |
| 2025-06-10 | Schmid John P. | A-Award | 19,000.00 | $4.01 | $76,190 |
| 2025-06-10 | LAPPE RODNEY W | A-Award | 19,000.00 | $4.01 | $76,190 |
No community reviews yet for DSGN.
Be the first — export the analysis to your AI and contribute back.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.207 · 22a3a690 · 2026-05-13 17:39:54